Alto Neuroscience (ANRO) Long-Term Debt Issuances (2024 - 2025)
Alto Neuroscience (ANRO) posted Long-Term Debt Issuances of -$18.9 million for Q3 2025, down 196.19% sequentially from $19.7 million in Q1 2025, and down 1556.77% YoY from $1.3 million in Q3 2024.
Powered by 
Analysis
Alto Neuroscience (ANRO) Long-Term Debt Issuances (2024 - 2025) Analysis & Trends
Alto Neuroscience has reported Long-Term Debt Issuances for 2 years, with the latest figure at -$18.9 million in Q3 2025.
- Quarterly Long-Term Debt Issuances fell 1556.77% year-over-year to -$18.9 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was -$18.9 million (down 184.97% YoY) and the FY2025 annual result came in at $750000.0, changed N/A from the prior year.
- Long-Term Debt Issuances slipped to -$18.9 million in Q3 2025 per ANRO's latest filing, from $19.7 million in the prior quarter.
- Over five years, Long-Term Debt Issuances peaked at $19.7 million in Q1 2025 and troughed at -$18.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Alto Neuroscience | 1.52 Bn | 1.52 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 19.69 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.30 Mn |